Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 93Terminated 23Recruiting 12Unknown 9Withdrawn 8Active not recruiting 7Not yet recruiting 3Suspended 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Colorectal Neoplasms 37Carcinoma, Hepatocellular 14Ovarian Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Stomach Neoplasms 3Rectal Neoplasms 3Neoplasm Metastasis 3Glioblastoma 3Recurrence 2Liver Neoplasms 2Diabetes Mellitus, Insulin-Dependent, 12 2Brain Neoplasms 2mCRC 1Uterine Cervical Neoplasms 1Unresectable Metastatic Colorectal Cancer 1Spinocerebellar Degenerations 1Small Cell Lung Carcinoma 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Rectal Neoplasms Malignant 1Proteinuria 1Platinum-sensitive Relapsed Ovarian Cancer 1Platinum-resistant Recurrent Ovarian Cancer (PROC) 1Platinum-resistant Recurrent Ovarian Cancer 1Osteosarcoma 1Non-small Cell Lung Cancer Patients with Brain Metastases 1Neutropenia 1Neoplastic Cells, Circulating 1NSCLC 1Metastatic Colorectal Cancer With Left-sided Primary Tumor 1Medulloblastoma 1

Interventions

Temozolomide 11Radiotherapy 4Magnetic Resonance Spectroscopy 4Specimen Handling 3Radiation 3Blood Specimen Collection 3Bevacizumab 3tislelizumab 2pembrolizumab 2cemiplimab 2Surgical Procedures, Operative 2mirdametinib 1gallium maltolate 1fluzoparib 1florbetapir 1elemene 1X-Rays 1Vortioxetine 1Transurethral Resection of Bladder 1Spironolactone 1Spinal Puncture 1Sitagliptin Phosphate 1Sampling Studies 1Receptors, Interleukin-8B 1Radiotherapy, Intensity-Modulated 1Psychosocial Intervention 1Platinum 1Photons 1Photochemotherapy 1Pharmaceutical Preparations 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Glioblastoma × Bevacizumab × Clear all
NCT07541781 2026-04-21

Sitagliptin in Recurrent/Progressive Grade 4 Glioma

University of Iowa

Phase 1 Not yet recruiting
45 enrolled
CNS

Glioblastoma, Glioma

NCT05540275 2023-10-06

Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma

Henan Provincial People's Hospital

Phase 2 Not yet recruiting
30 enrolled
CNS

Glioblastoma

NCT05502991 2022-09-27

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma

Henan Provincial People's Hospital

Phase 2 Not yet recruiting
60 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡